Bayer Receives MHRA Approval for Lynkuet (elinzanetant), the First-in-Class Dual Neurokinin Receptor Antagonist for Moderate-to-Severe Menopausal Vasomotor Symptoms

Recently,Bayer recently announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Lynkuet (elinzanetant) for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) associated with menopause.According to the press release, Lynkuet is the first approved dual neurokinin (NK) targeted therapy. The therapy's marketing application is also under review by regulatory authorities in the United States and the European Union.

Vasomotor Symptoms (VMS; also known as hot flashes)Hot flashes are one of the most commonly reported symptoms of menopause.Menopause is a physiological transitional stage for women, expected to affect 1.2 billion women globally by 2030. The symptomIs produced byDue to the lack of estrogen, KNDy neurons become hypertrophic, and the body temperature regulation pathway they mediate is excessively activated. The lack of estrogen can result from natural menopause, bilateral oophorectomy, or drug intervention through endocrine therapy that leads to progressive decline in ovarian function.

Hot flashes have also been shown to negatively impact women's quality of life and are one of the main reasons women seek medical help.Up to 80% of women experience VMS at some point during the menopausal transition, which is the primary reason for seeking medical attention during this specific phase of a woman's life.More than one-third of women report severe symptoms, which can persist for 10 years or longer after their final menstrual period.

Therefore, providing more treatment options to help women address these symptoms will be very important. Bayer will also submit marketing authorization applications for elinzanetant to other health regulatory authorities for the treatment of moderate to severe VMS symptoms associated with menopause.

"King of Antihypertensives" Misses Centralized Procurement, Will Generic Drug Companies Face Even Tougher Times?

Challenge the Global "Blockbuster Drug" in Autoimmune Diseases! Chinese Innovative Pharmaceutical Companies Seek to Break Through

New Development | Another Director of the Medical Insurance Bureau Turns Himself In